Corporate ActionJun 30, 2026, 09:26 AM
Biodexa Prices $3.5M Registered Direct Offering & Private Placement
AI Summary
Biodexa Pharmaceuticals Plc announced the pricing of a combined offering expected to generate approximately $3.5 million in gross proceeds. The offering includes a registered direct offering of ADSs or pre-funded warrants, a concurrent private placement of pre-funded warrants and Series M/N warrants, and a warrant inducement resulting in the issuance of Series O warrants. The Series M, N, and O warrants will become exercisable upon receipt of shareholder approval. The company plans to use the net proceeds to fund its development programs, for working capital, and other general corporate purposes.
Key Highlights
- Biodexa Pharmaceuticals priced a combined offering to raise approximately $3.5 million in gross proceeds.
- The Registered Offering includes 282,952 ADSs or pre-funded warrants at an offering price of $2.85 per ADS.
- The Concurrent Private Placement involves pre-funded warrants for 350,877 ADSs and Series M/N warrants for 984,706 ADSs.
- Series M and N Warrants are exercisable at $2.85 per ADS, becoming exercisable upon shareholder approval.
- A warrant inducement led to the exercise of 609,756 existing warrants at a reduced price of $2.85 per ADS.
- In return for the inducement, 1,219,512 Series O Warrants will be issued, exercisable at $2.85 per ADS, pending shareholder approval.
- The company intends to use the net proceeds to fund development programs, for working capital, and general corporate purposes.
- Maxim Group LLC acted as the exclusive placement agent, receiving an 8.0% cash fee on gross proceeds.
Price Impact
More from BDRX